Narrow search
Showing 11 - 20 of 28
Cover Image
Properties of a mean residual life function arising from renewal theory
Jedenius, Erik; Wimo, Anders; Strömqvist, Jan; … - In: Naval research logistics : an international journal 57 (2010) 4, pp. 373-380
Persistent link: https://www.econbiz.de/10008403343
Cover Image
Cost-effectiveness of alendronate in the treatment of osteoporois in Denmark : an economic evaluation based on the fracture intervention trial
Jönsson, Linus (contributor);  … - 2002 - [Elektronische Ressource]
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...
Persistent link: https://www.econbiz.de/10001673640
Cover Image
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil : a longitudinal naturalistic cohort
Gustavsson, Anders; Jönsson, Linus; Parmler, Johan; … - In: The European journal of health economics : HEPAC ; … 13 (2012) 5, pp. 561-568
Persistent link: https://www.econbiz.de/10009657337
Cover Image
Hälsoekonomiska utvärderingar som underlag för beslut om pris och subventionering: Riktlinjer och beslutskriterier
Jönsson, Bengt; Lundkvist, Jonas - 2002
Persistent link: https://www.econbiz.de/10010281197
Cover Image
Risk and mortality of recurrent breast cancer in Stockholm 1985 - 2005
Lundkvist, Jonas; Kasteng, Frida; Lidgren, Mathias; … - 2007
The purpose of this study was to estimate the risk and mortality of breast cancer recurrences in Swedish women, and to analyse changes over time and variations between patients in different risk groups. Such estimates are of key importance for modelling the cost-effectiveness of different...
Persistent link: https://www.econbiz.de/10010281338
Cover Image
Kostnadseffektivitet hos nya läkemedel: En systematisk genomgång av publicerade studier för NCEs registrerade i Sverige 1987 - 2000
Jönsson, Bengt; Lundkvist, Jonas - 2002
Persistent link: https://www.econbiz.de/10010281384
Cover Image
Nya läkemedel i Sverige: Innovationshöjd, prissättning och marknadsframgång
Jönsson, Bengt; Lundkvist, Jonas; Persson, Björn - 2002
Persistent link: https://www.econbiz.de/10010281424
Cover Image
The costs and benefits of regulations for reimbursement of new drugs
Lundkvist, Jonas; Jonsson, Bengt; Rehnberg, Clas - In: Health Policy 79 (2006) 2-3, pp. 337-344
Persistent link: https://www.econbiz.de/10005520149
Cover Image
Risk and Mortality of Recurrent Breast Cancer in Stockholm 1985-2005
Jönsson, Bengt; Lundkvist, Jonas; Kasteng, Frida; … - Economics Institute for Research (SIR), … - 2007
The purpose of this study was to estimate the risk and mortality of breast cancer recurrences in Swedish women, and to analyse changes over time and variations between patients in different risk groups. Such estimates are of key importance for modelling the cost-effectiveness of different...
Persistent link: https://www.econbiz.de/10005423797
Cover Image
Kostnadseffektivitet hos nya läkemedel. En systematisk genomgång av publicerade studier för NCEs registrerade i Sverige 1987-2000.
Jönsson, Bengt; Lundkvist, Jonas - Economics Institute for Research (SIR), … - 2002
Hälsoekonomiska utvärderingar som bedömer kostnadseffektiviteten av läkemedel blir allt vanligare inom hälso- och sjukvården som underlag för beslut om läkemedelsanvändning. Antalet publicerade hälsoekonomiska studier har ökat kraftigt från slutet av 80-talet, men fördelningen av...
Persistent link: https://www.econbiz.de/10005649439